| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,985 | 1,083 | 18.11. |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10.11. | Saniona AB: Saniona sells AstronauTx shareholding for GBP 3.36 million (SEK 44.5 million) | 137 | GlobeNewswire (Europe) | Saniona (OMX: SANION), a clinical-stage biopharmaceutical company focused on neurological and psychiatric disorders, today announces that it has agreed to sell its entire shareholding in AstronauTx... ► Artikel lesen | |
| 06.11. | Saniona AB: Saniona successfully completes Phase 1-enabling work for SAN2668 | 130 | GlobeNewswire (Europe) | Saniona (OMX: SANION), a clinical-stage biopharmaceutical company focused on neurological and psychiatric disorders, today announces the successful completion of the preclinical and CMC work required... ► Artikel lesen | |
| 02.11. | Saniona AB: Bulletin from the Saniona AB extraordinary shareholders' meeting on November 2, 2026 | 266 | GlobeNewswire (Europe) | Today, on 2 November 2026, the extraordinary shareholders' meeting was held in Saniona AB. A summary of the adopted resolutions follows below.
Resolution on authorization for the board of directors... ► Artikel lesen | |
| SANIONA Aktie jetzt für 0€ handeln | |||||
| 13.10. | Saniona AB: Saniona announces new preclinical data reinforcing SAN2465's potential as a rapid-acting antidepressant | 216 | GlobeNewswire (Europe) | Saniona (OMX: SANION), a clinical-stage biopharmaceutical company focused on neurological and psychiatric disorders, today announces that SAN2465 significantly enhanced hippocampal synaptic plasticity... ► Artikel lesen | |
| 24.09. | Saniona AB: Saniona completes toxicology and CMC studies for SAN2465, enabling IND submission by October 2026 | 403 | GlobeNewswire (Europe) | Saniona (OMX: SANION), a clinical-stage biopharmaceutical company focused on neurological and psychiatric disorders, today announces the successful completion of the toxicology, chemistry, manufacturing... ► Artikel lesen | |
| 27.08. | Jetzt zählt die Pipeline: Saniona verbrennt Millionen - jetzt hängt alles an diesen zwei Wirkstoffen | 769 | wallstreetONLINE | © Foto: OpenAISaniona schreibt deutlich höhere Verluste, verfügt aber über 43,8 Millionen Euro Cash und setzt nun auf zwei zentrale Wirkstoffkandidaten Enthaltene Werte: SE0005794617Den vollständigen... ► Artikel lesen | |
| 27.08. | Saniona AB Q2 Loss Increases | 4 | RTTNews | ||
| 27.08. | Saniona AB: Saniona publishes its interim report for the second quarter of 2026 | 415 | GlobeNewswire (Europe) | Three Months Ended June 30, 2026 (2025)Six Months Ended June 30, 2026 (2025)Revenue was SEK 4.5 M (9.3 M)Revenue was SEK 9.2 M (19.1 M)Operating profit/loss was SEK -60.3 M (-25.9 M)Operating profit/loss... ► Artikel lesen | |
| 10.08. | Saniona AB: AstronauTx exercises option from Saniona to acquire worldwide rights to neurological disease program under research collaboration | 785 | GlobeNewswire (Europe) | Development candidate ATX0926 enters IND-enabling stage of development expanding AstronauTx's pipeline of therapies targeting sleep biologyRepresents the successful outcome of a multi-year scientific... ► Artikel lesen | |
| 27.05. | Saniona AB: Bulletin from the Saniona AB annual shareholders' meeting on May 27, 2026 | 334 | GlobeNewswire (Europe) | Today, on May 27, 2026, the annual shareholders' meeting was held in Saniona AB. A summary of the adopted resolutions follows below.
Resolution on adoption of accounts and distribution of the company's... ► Artikel lesen | |
| 26.05. | Saniona AB: Saniona publishes its interim report for the first quarter of 2026 | 340 | GlobeNewswire (Europe) | Q1 2026 (Q1 2025)Revenue was SEK 4.6 M (9.8 M)Cash and cash equivalent SEK 532.0 M (260.7)Operating profit/loss was SEK -56.5 M (-16.5 M)Basic earnings/loss per share was SEK -0.33 (0.17)Net profit/loss... ► Artikel lesen | |
| 26.02. | Saniona AB: Saniona publishes its year-end report for 2025 | 286 | GlobeNewswire (Europe) | Three Months Ended December 31, 2025 (2024)Twelve Months Ended December 31, 2025 (2024)Revenue was SEK 4.6 M (313.4 M)Revenue was SEK 434.4 M (334.7 M)Operating profit/loss was SEK -46.5 M (290.4 M)Operating... ► Artikel lesen | |
| 27.11.25 | Saniona AB: Saniona publishes its interim report for the third quarter of 2025 | 343 | GlobeNewswire (Europe) | Three Months Ended September 30, 2025 (2024)Nine Months Ended September 30, 2025 (2024)Revenue was SEK 410.7 M (7.2 M)Revenue was SEK 429.8 M (21.3 M)Operating profit/loss was SEK 359.9 M (-18.9 M)Operating... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 2,728 | -0,80 % | Evotec-Aktie: Gewinn- und Umsatzrekord? | Die Aktie des Hamburger Wirkstoffforschers Evotec bleibt ein spannender, aber risikoreicher Titel am deutschen Aktienmarkt. Nach schwierigen Monaten sorgen erste operative Fortschritte, neue Partnerschaften... ► Artikel lesen | |
| NANOREPRO | 1,395 | -0,71 % | NanoRepro nach starkem H1-Bericht: Diese Marke entscheidet jetzt | ||
| PALATIN TECHNOLOGIES | 5,150 | 0,00 % | Palatin targets phase I start in first half of calendar 2027 for lead MC4R lipidated peptide | ||
| BRAIN BIOTECH | 2,500 | +0,81 % | Brain Biotech bestätigt 9M-Zahlen: Warum der große Deal nicht reicht | ||
| AAP IMPLANTATE | 1,440 | -3,36 % | aap Implantate - Aktie vor Neubewertung? CEO und COO im Interview: "Die Basis steht, jetzt schalten wir auf Wachstum." | Eine spannende Sondersituation zeichnet sich derzeit bei der aap Implantate AG (ISIN: DE000A3H2101) ab: Nach Jahren der Restrukturierung und hohen regulatorischen Aufwendungen hat der Berliner Spezialist... ► Artikel lesen | |
| CO.DON | 0,005 | -28,57 % | EQS-AFR: CO.DON AG i.l.: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: CO.DON AG i.l.
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
CO.DON AG i.l.: Vorabbekanntmachung über die... ► Artikel lesen | |
| BIOXXMED | 0,800 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM XETRA - 30.10.2026 | The following instruments on XETRA do have their last trading day on 30.10.2026Die folgenden Instrumente in XETRA haben ihren letzten Handelstag am 30.10.2026ISIN NameDE000A41YD32 BIOXXMED AG INH O.N.DE000HLB78G8... ► Artikel lesen | |
| CLINUVEL | 4,350 | -1,14 % | CLINUVEL PHARMACEUTICALS LIMITED: Change in substantial holding - Updated | ||
| SANGAMO THERAPEUTICS | 0,126 | -100,00 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Selects Successful Bidders Following Competitive Asset Auction for $163.55 Million in Cash Consideration at Closing and Up to $100 Million in Potential Milestones | PTC Therapeutics to purchase Fabry disease program, isaralgagene civaparvovec Lilly to purchase capsid delivery, zinc finger and modular integrase (MINT) platforms and prion disease program Proposed... ► Artikel lesen | |
| BIO-GATE | 2,100 | -3,67 % | Original-Research: Bio-Gate AG (von BankM AG): Kaufen | Original-Research: Bio-Gate AG - von BankM AG
10.11.2026 / 12:44 CET/CEST
Veröffentlichung einer Research, übermittelt durch EQS News - ein Service der EQS Group.
Für den Inhalt der Mitteilung... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 5,150 | +3,00 % | COSCIENS Biopharma Inc. Q3 Loss Widens | ||
| EDITAS MEDICINE | 1,675 | +3,40 % | Editas Medicine, Inc.: Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia | Phase 1/2 clinical trial of EDIT-401 cleared to initiate dosing in patients who require additional LDL-C lowering Company remains on track to begin patient dosing this year and report initial safety... ► Artikel lesen | |
| EXELIXIS | 62,81 | +0,95 % | Where Will Exelixis Be in 5 Years? 1 Experimental Drug Could Change Everything | ||
| EVONEXT | 2,460 | 0,00 % | Adhoc: EvoNext Holdings SA: EvoNext Holdings SA makes available the audited financial statements of Ascend Sport Technology AG for 2025/26 | EvoNext Holdings SA / Key word(s): Merger
EvoNext Holdings SA makes available the audited financial statements of Ascend Sport Technology AG for 2025/26
16-Nov-2026 / 07:00 CET/CEST
Release... ► Artikel lesen | |
| GERON | 0,895 | -1,52 % | Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |